Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.61 |
| ▸ | DRD2 | P14416 | 5/20 | 0.56 |
| ▸ | DRD3 | P35462 | 5/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | ACHE | P22303 | 3/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8766729 | 0.92 | MTNR1B (0.55) | MTNR1AMTNR1BDRD2DRD3CA1 | |
| SCHEMBL8766720 | 0.92 | MTNR1B (0.55) | MTNR1AMTNR1BDRD2DRD3CA1 | |
| SCHEMBL629694 | 0.82 | DRD3 (0.51) | MTNR1AMTNR1BDRD2DRD3CA1 | |
| SCHEMBL5485492 | 0.82 | DRD2 (0.66) | MTNR1AMTNR1BDRD2DRD3CA1 | |
| SCHEMBL629819 | 0.80 | HRH3 (0.52) | — | |
| SCHEMBL30612403 | 0.79 | MTNR1A (0.53) | MTNR1AMTNR1BDRD2HTR2C | |
| SCHEMBL6405616 | 0.78 | DRD2 (0.57) | MTNR1AMTNR1BDRD2DRD3CA1 | |
| SCHEMBL345882 | 0.77 | MTNR1A (0.60) | MTNR1AMTNR1BDRD2DRD3CA1 | |
| SCHEMBL8603880 | 0.77 | MTNR1A (0.60) | MTNR1AMTNR1BDRD2DRD3CA1 | |
| SCHEMBL345881 | 0.77 | MTNR1A (0.60) | MTNR1AMTNR1BDRD2DRD3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | MTNR1A 2060/4885MTNR1B 1619/4885DRD2 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.